Oncology News
-
Showcase
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
-
Showcase
Mobile Mammography
bout two years after the outbreak of COVID-19, many resources are still being used in the fight against this new virus. Nevertheless, the number of breast cancer cases in Italy are still very high: according to the report “The numbers of cancer in Italy”, published by AIRTUM and AIOM, in 2020 about 55.000 new cases were diagnosed in Italy among women (as of today, estimates for 2021 ...
-
Showcase
RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country
RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in ...
By RTsafe
-
Showcase
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine ...
-
Showcase
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest that onapristone adds to inhibition ...
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Showcase
Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida
DAYTONA BEACH, Fla., Nov. 1, 2021 /PRNewswire/ -- Koning begins an FDA screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally. "This FDA screening trial is a major ...
-
Showcase
RTsafe and Biomedic Medical Group sign exclusive agreement for distribution
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China. We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese radiotherapy professionals. ...
By RTsafe
-
Showcase
succeSRS Dosimetry Audit Service
RTsafe launches the Dosimetry Audit Service – succeSRS The complex nature of the stereotactic treatment process demands commitment to the highest levels of accuracy and precision. That being the case we are thrilled to announce the launch of our new dosimetry audit service aiming to promote a culture of excellence. succeSRS is a powerful tool for quality improvement in intracranial ...
By RTsafe
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Showcase
Northern Arizona, Verde Valley MC Highlights VeraForm; Importance Marking Breast Surgical Site
As a patient facing breast cancer surgery, you should know that precise "marking" of your cancer surgical site is an important part of your treatment. A marker is a device inserted at the surgical site. Precision in marking helps make sure you retain as much normal breast tissue as possible with the surgery. This ultimately leads to best overall post-surgical care by your wellness team. A new ...
-
National Cancer Prevention Month and Protecting Workers and Building Occupants in Puerto Rico from Carcinogens
The International Agency for Research on Cancer reports that as recently as 2020, there were over 13,000 new cases of cancer in Puerto Rico. Tragically, there were also more than 5,500 deaths due to cancer in Puerto Rico that year alone. The American Association for Cancer Research has reported that more than 40% of all diagnosed cancers in the U.S. can be attributed to preventable causes. ...
-
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
-
Synaptive’s Modus X Takes Center Stage in the latest issue of the Journal of Neurosurgery’s Neurosurgical Focus on exoscopes in neurosurgery
January’s Journal of Neurosurgery (JNS) published a series of 17 videos that examine the application of exoscopic visualization in cerebrovascular, neuro-oncologic, pediatric, peripheral nerve, and spinal neurosurgery. The video series highlights the exoscope as a versatile alternative to traditional optical microcopy. Seven of the videos highlight the use of Synaptive’s robotic ...
-
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial ...
By eTheRNA
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
Creative Proteomics Unleashes the Exosome Untargeted Metabolomics Service
Creative Proteomics, the globally recognized proteomics, metabolomics, and multi-omics service provider, is delighted to introduce its exosome untargeted metabolomics services—a premier-stage offering in their broad catalogue services. Exosomes are tiny extracellular vesicles, hosting a diverse array of molecules including proteins, RNAs, and metabolites. With a diameter ranging between ...
-
Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant
Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...
-
ATMP Sterility Testing
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
-
Biopharma PEG Assists ADC Development with Monodispersed PEGs
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and more.ADCs ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you